The Brief

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV infusions.

Keytruda Qlex showed similar effectiveness to the IV version in clinical trials.

The new version is expected to launch in late September.

WASHINGTON - The U.S. Food and Drug Administration said it has approved a new formulation of Merck's cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy.

The latest announcement could provide added convenience and potentially improve a patient’s experience.

Keytruda Qlex gets FDA approval

The new version, called Keytruda Qlex, is an injection tha

See Full Page